ResearcherHokkaido UniversityActive in the last 2 years
Kazuaki Harada
Matched on ORCID iD 0000-0001-9577-1884; OpenAlex author ID A5029924703. Sources: OpenAlex.
Their work
- Papers
- 8
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 50
2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 2 papers
Papers 8
- Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geria… Co-author DOI 10.1093/jjco/hyag055↗
- Co-targeting an AMPK–MAPK axis reprograms fibroblasts and suppresses PDAC Co-author DOI 10.64898/2026.03.16.711738↗
- Lack of association between SLFN11 expression and treatment efficacy or survival outcomes in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-025-06216-8↗
- Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pa… Co-author DOI 10.3390/jcm12041596↗
- Analysis of the Pancreatic Cancer Microbiome Using Endoscopic Ultrasound-Guided Fine-Needle Aspiration-Derived Samples. Co-author DOI 10.1097/mpa.0000000000002028↗
- Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan… Co-author DOI 10.1136/bmjopen-2021-048833↗
- A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403). Co-author DOI 10.1002/onco.13838↗
- Comparison of FOLFIRINOX, Gemcitabine Plus Nab-Paclitaxel, and Chemoradiotherapy as First-Line Treatments for Locally Advanced Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-356113/v1↗
Closest collaborators
The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yoshito Komatsu · 6 shared papers, 2021–2025 · strength 0.87
- Paper Lack of association between SLFN11 expression and treatment efficacy or survival outcomes in patients with pancreatic d… DOI 10.1007/s00432-025-06216-8↗
- Paper Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotec… DOI 10.3390/jcm12041596↗
- Paper Comparison of FOLFIRINOX, Gemcitabine Plus Nab-Paclitaxel, and Chemoradiotherapy as First-Line Treatments for Locally A… DOI 10.21203/rs.3.rs-356113/v1↗
- Yasuyuki Kawamoto · 6 shared papers, 2021–2026 · strength 0.81
- Paper Co-targeting an AMPK–MAPK axis reprograms fibroblasts and suppresses PDAC DOI 10.64898/2026.03.16.711738↗
- Paper Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotec… DOI 10.3390/jcm12041596↗
- Paper Comparison of FOLFIRINOX, Gemcitabine Plus Nab-Paclitaxel, and Chemoradiotherapy as First-Line Treatments for Locally A… DOI 10.21203/rs.3.rs-356113/v1↗
- Shintaro Nakano · 5 shared papers, 2021–2023 · strength 0.62
- Paper Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotec… DOI 10.3390/jcm12041596↗
- Paper Comparison of FOLFIRINOX, Gemcitabine Plus Nab-Paclitaxel, and Chemoradiotherapy as First-Line Treatments for Locally A… DOI 10.21203/rs.3.rs-356113/v1↗
- Paper A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Panc… DOI 10.1002/onco.13838↗
- Naoya Sakamoto · 4 shared papers, 2021–2023 · strength 0.49
- Paper Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotec… DOI 10.3390/jcm12041596↗
- Paper A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Panc… DOI 10.1002/onco.13838↗
- Paper Analysis of the Pancreatic Cancer Microbiome Using Endoscopic Ultrasound-Guided Fine-Needle Aspiration-Derived Samples. DOI 10.1097/mpa.0000000000002028↗
- Naoya Sakamoto · 2 shared papers, 2021–2025 · strength 0.38
- Paper Lack of association between SLFN11 expression and treatment efficacy or survival outcomes in patients with pancreatic d… DOI 10.1007/s00432-025-06216-8↗
- Paper Comparison of FOLFIRINOX, Gemcitabine Plus Nab-Paclitaxel, and Chemoradiotherapy as First-Line Treatments for Locally A… DOI 10.21203/rs.3.rs-356113/v1↗
- Masaki Kuwatani · 2 shared papers, 2022–2026 · strength 0.30
- Kazumichi Kawakubo · 2 shared papers, 2022–2026 · strength 0.30
- Tetsuhito Muranaka · 2 shared papers, 2021–2023 · strength 0.26
- Paper Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotec… DOI 10.3390/jcm12041596↗
- Paper A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Panc… DOI 10.1002/onco.13838↗
- Yuh Sakata · 2 shared papers, 2022–2023 · strength 0.26
- Paper Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotec… DOI 10.3390/jcm12041596↗
- Paper Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination c… DOI 10.1136/bmjopen-2021-048833↗
- Takeaki Nakamura · 1 shared paper, 2025 · strength 0.25
- Shingo Kagawa · 1 shared paper, 2026 · strength 0.20
- Amane Takahashi · 1 shared paper, 2026 · strength 0.20
- Shiho Arima · 1 shared paper, 2026 · strength 0.20
- Masaaki Murakawa · 1 shared paper, 2026 · strength 0.20
- Shintaro Yagi · 1 shared paper, 2026 · strength 0.20
- Toru Otsuru · 1 shared paper, 2026 · strength 0.20
- Yusuke Sano · 1 shared paper, 2026 · strength 0.20
- Keiko Kamei · 1 shared paper, 2026 · strength 0.20
- Nobumasa Mizuno · 1 shared paper, 2026 · strength 0.20
- Hidetoshi Eguchi · 1 shared paper, 2026 · strength 0.20
- Hirofumi Akita · 1 shared paper, 2026 · strength 0.20
- Naohiro Okano · 1 shared paper, 2026 · strength 0.20
- Naoto Gotohda · 1 shared paper, 2026 · strength 0.20
- Shigeru Marubashi · 1 shared paper, 2026 · strength 0.20
- Masato Ozaka · 1 shared paper, 2026 · strength 0.20
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.